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Diabetes mellitus (DM) is a major public health problem worldwide. The aim is to assess the 
early detection of impaired nerve function and the risk factors associated with the 
development of diabetic neuropathy.  
Methods 
It is a prospective descriptive study of age-matched 263 diabetic Saudi patients from the 
outpatient clinic of the Diabetic Centre in King Fahd Hospital in Almadinah Almunawwarah 
in Kingdom of Saudi Arabia during 2008-2009. Written informed consent was obtained from 
each subject after the protocol was approved by the local ethics committee. All subjects were 
diagnosed as diabetics using WHO criteria. We obtained detailed demographic data as age, 
sex, special habits, height, weight and body mass index, arterial blood pressure, type and 
duration of diabetes, glycosated haemoglobin (HbA1C), lipid profile, management, family 
history of hypertension, diabetes. Assessment of neuropathy by using the Diabetic 
neuropathy index and diabetic neuropathy score. Asymptomatic patients who scored less 
than two in clinical examination were referred to be assessed by complete neurological 
examination, and nerve conduction studies. Data were calculated and compared by using 
SPSS version 13.0.  
Results 
The type I were 39 (14.8%) and type II were 244 (85.2%) diabetic patients and the mean 
duration of diabetes mellitus in all diabetic patients was 13.89 ± 8.7 years. The symptomatic 
diabetic neuropathy patients were 165 (62.7%) out of 263 diabetic patients and the 
asymptomatic were 98 (37.3%). The risk factors for neuropathy were old age, poor blood 
sugar control, long duration of diabetes, hyperlepidemia, Body Mass Index (BMI). There 
were no statistical significant differences in relation to types of diabetes mellitus. There was 
positive correlation which shown by the linear regression charts between the grades of nerve 
conduction defects in asymptomatic diabetic neuropathy patients and duration of diabetes, 
age, BMI and HbA1C. 
Conclusion 
The early detection of by sub-clinical nerve conduction of diabetic patients is of a major 
clinical interest that could lead to more intensive supervision of diabetic patients. Further 
studies should be performed in order to confirm these findings. 
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iabetes mellitus (DM) is a major public 
health problem worldwide. The World 
Health Organization has estimated that, the 
number of adults with diabetes in the 
world would increase alarmingly from 
135million in 1995 to 300 million in 20251. 
One study has shown that the prevalence 
of DM is about (23.7%) in 2004 in Kingdom 
of Saudi Arabia and another recent study 
has shown that there is a significant 
increase in the prevalence which became 
30% in 2011 where was 34.1% in males and 
27.6% in females2-3.  
Diabetic peripheral neuropathy considered 
as one of the commonest complications 
seen in up to 50% of affected patients with 
type 1 and type 2 DM leading to substantial 
morbidity, discomfort and associated with 
increased mortality according to its 
severity4,5. 
Nerve conduction studies, primarily nerve 
conduction velocities are considered one of 
the most sensitive indices of the severity of 
neuropathy and were used to localize 
lesions and to describe the type and 
severity of the pathophysiological process, 
including alterations in function that are 
not recognized clinically6. 
The aim of this research was to study the 
prevalence of asymptomatic diabetic 
neuropathy in Almadinah Almunawwarah 
in the Kingdom of Saudi Arabia as an 
example of the western district and find 
out the prevalence of the associated risk 
factors with symptomatic and 
asymptomatic diabetic neuropathy.  
 
Material and Methods 
 
It is a prospective descriptive study, the 
protocol was approved by the local ethics 
committee and written informed consent 
was obtained from each patient who 
attended the outpatient clinic of the 
Diabetic Patients Medical Centre in king 
Fahad hospital in Almadinah 
Almunawwarah in Kingdom of Saudi 
Arabia in the academic year of 2008/2009. 
All subjects diagnosed as diabetics using 
international standard criteria7-10.  
We obtained detailed demographic data as 
age, sex, special habits, height, weight and 
body mass index, arterial blood pressure, 
type and duration of diabetes, glucosated 
haemoglobin (HbA1C), lipids profile, 
management, family history of 
hypertension, diabetes. Neuropathy was 
assessed by using the Michigan 
Neuropathy program which includes two 
steps; the Diabetic Neuropathy Index (DNI) 
and the Diabetic Neuropathy Score (DNS). 
Patients who scored less than 2 on routine 
clinical examination and were 
asymptomatic were referred to be assessed 
by complete neurological examination 
done by neurologist, and nerve conduction 
studies (Appendices 1 and 2). 
The electrophysiological tests were 
performed by the same neurophysiologist, 
and he was blinded to the clinical 
information of the subjects. The procedures 
were explained for the patient, and all 
nerve-conduction tests were performed in 
the same room with a comfort temperature 
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We used The XL Calibre Ltd EMG system to 
perform the recording. The optimal 
recording amplifier frequency range of 50 
Hz. to 10 KHz and a standard sensitively of 
100 to 500 UV. Nerve conduction velocity 
was assessed in Median, ulnar, peroneal, 
sural nerve and posterior tibial nerves 
Motor nerve conduction velocity was 
measured on the left forearm segment of the 
median nerve (thenar muscle), and the left 
peroneal nerve (extensor digitorum brevis 
and tibial anterior muscle)12-14. Minimal F-
wave latencies were acquired from the same 
recording and distal stimulation points, 
from at least eight tracings. F-wave 
conduction velocity was calculated as 
described elsewhere data were collected, 
calculated and statistical analyses were 
carried out by using Statistical Package for 
Social Sciences (SPSS version XIII, Inc., 
Chicago, Illinois). Results were considered 
statistically significant at P-value less than 




The 263 diabetic Saudi patients distributed 
as follows: type I was 39 (14.8) and type II 
was 224 (85.2%) and the mean duration of 
diabetes mellitus was 13.89 ± 8.7 years. The 
distribution of the patients according to 
their gender and type of diabetes were 15 
(51.7%) males in type I and 14 (47.3%) 
females, and type II they were 107 (45.7%) 
males and 127 (54.3%) females. The positive 
family history of diabetes was 66.9% and for 
the hypertension was 33.5%. The non-
smokers representing 86.7%.  
There were 122 males and 141 females’ with 
male to female ratio of 1:1.15, aged 20-70 
years (51.79 ± 10.88 years). The patients with 
neuropathy were 155 (58.9%) and 108 
(41.1%) diabetic patients were free from 
signs and symptoms of neuropathy as 
assessed initially by the DNI. Further 
assessment by the DNS and the neurological 
examinations added 10 more patients 
(3.8%). So, patients became 165 (62.7%) and 
those clinically free 98 (37.3%). The positive 
DN patients diagnosed by electrophysio-
logical studies were 43 (16.4.) The results 
show that positive family history of diabetes 
was seen in 115 patient (69.6%) and 54 
(55.1%), the smokers number and 
percentage were 13 (0.07%) and 3 (0.03%) 
while type II represented as 146 (88.4%) and 
78 (79.5) in the symptomatic and 
asymptomatic DN patients respectively. The 
symptomatic DN diabetic patients mean 
BMI was 33.42 ± 5.68 and that of 
asymptomatic was 33.45 ± 6.88 which makes 
them more susceptible to chronic disease 
e.g. hypertension and diabetes mellitus 
complications. The mean systolic blood 
pressure among symptomatic and the 
asymptomatic DN patients were (140.19 ± 
18.30 and 138.77 ± 21.21mmHg) and the 
mean diastolic were respectively (83.30 ± 
11.37 and 81.22 ± 9.47 mmHg). Hypertensive 
family history was 61 patients (36.9%) 
positive in symptomatic and 28 (28.5%) in 
asymptomatic patient. 
On the other hand, we found that HbA1C 
was higher in symptomatic DN patients 
(10.06 ±1.91) symptomatic to (8.58 ±1.41) in a 
symptomatic patients indicated worst 
glucose control in the first group. We also 
revealed that there were more hyper-
lepidemic symptomatic patients 47 (28.4) 
and has asymptomatic which were 29 (29.5), 
where the total cholesterol, triglycerides and 
the LDL were higher than the normal values 
in both groups (Table 1).  
The results show that the mean risk score for 
the females (2.88± 4.18) was higher than the 
males (1.77 ± 4.30) with no statistical 
differences (Figure 1). 
The number of patients, who were clinically 
asymptomatic and diagnosed electro-
physiologically, was as mild, moderate, and 
severe nerve conductions defect as shown in 
(Figure 2).  
There was a positive correlation shown by 
the linear regression charts between the 
grades of asymptomatic patients and the 
diabetes mellitus duration, glycosated 
haemoglobin, age and BMI of the nerve 
conduction defects among clinically free 
diabetic neuropathy (Figure 3).-----------------
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Table 1: comparison between the diabetic neuropathy patients and the asymptomatic patients 






N (%) 98 
Symptomatic diabetic 
neuropathy 
N (%) 165 
Age 49.84 ± 11.85 52.90 ± 10.21 
Males: females ratio 1: 1.1 1:1.22 
Dm duration 12.05 ± 7.43 14.32 ± 8.39 
Type ii 78 (79.5) 146 (88.4) 
Family history of 
hypertension 28 (28.5) 61 (36.9) 
Family history of dm 54 (55.1) 115 (69.6) 
Smokers (non-smokers) 3 (0.03) 13 (0.07) 
Body mass index 33.45 ± 6.88 33.42 ± 5.68 
Systolic blood pressure 138.77 ± 21.21 140.19 ± 18.30 
Diastolic blood pressure 81.22 ± 9.47 83.30 ± 11.37 
Glucosated haemoglobin 8.58 ± 1.41 10.06 ± 1.91 
Hyperlepidemia 29 (29.5) 47 (28.4) 
Total cholesterol 5.36 ± 1.04 5.68 ± 1.30 
Triglyceride 2.24 ± 0.90 2.78 ± 1.17 





Figure 1: The box plot chart shows the female and the male diabetic patients mean values risk factors score. 
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Figure 2: The column with a cylindrical shape charts shows the grades of nerve conduction defects in 
clinically free diabetic neuropathy (asymptomatic) patients. 
 
A- the diabetes mellitus duration B- the glucosated haemoglobin 
  
C- the age in years D- body mass index (bmi) 
  
 
Figure 3: The linear regression charts showing correlation between different risk factors (A- the diabetes 
mellitus duration, B- the glucosated haemoglobin, C- the age, D- the BMI) and the grades of the nerve 
conduction defects among clinically free diabetic neuropathy (asymptomatic) patients.  
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Discussion 
 
Our study has endeavoured to provide a 
part of the picture of the sub clinical pattern 
of diabetic neuropathy in DM from 
Kingdom of Saudi Arabia as a developing 
area in the Middle East. Polyneuropathy 
prevalence varies greatly depending on the 
clinical and the electrophysiological 
diagnostic criteria of ADA9-10. The 
electrophysiological measu-res include the 
studies of sensory and motor nerve 
conduction, F-wave recordings, and surface 
electrodes electromyography. In Kingdom 
of Saudi Arabia, the prevalence of diabetic 
neuropathy was observed to be 35.9% after 
screening 1000 diabetics17. 
From our results we found that the diabetic 
neuropathy is mainly in sensory nerves 
more than motor nerves particularly in the 
lower limbs, which affect the small caliber 
nerves as sural nerve, and the abnormalities 
were in the nerve conduction velocity, 
latencies, and F-wave studies results, rather 
than in the amplitudes, as well it was more 
in type II diabetes mellitus Patients 
The early diagnosis of diabetic poly neuro-
pathy (DPN) is important in that it allows 
for immediate interventions, which decrease 
both mortality and morbidity a rise in the 
prevalence of the commonly associated 
complications, namely the various forms of 
diabetic neuropathy, is therefore 
anticipated18-22. The present study focused 
on a group of type II and type I diabetic 
patients who were free from neurologically 
symptoms. Diagnosis of DPN on clinical 
ground alone is not accurate and there is 
difficulty in detecting a small alteration of 
neuropathy23-24. 
Therefore, as a surrogate measure, nerve 
conduction study (NCS) is widely used as 
an evaluation of DPN. In general, it has been 
accepted that the ideal diagnosis of DPN is 
made by both the compatible clinical 
findings and the related electrophysiological 
changes25. 
Diabetes is the leading cause of neuropathy 
in the Western world, and neuropathy is the 
most common complication and greatest 
source of morbidity and mortality in 
diabetes patients26. It is estimated from a 
comprehensive collection of epidemiologic 
studies that the prevalence of neuropathy in 
diabetes patients is approximately 30% in 
hospital patients and 20% in community 
patients22. The overall annual incidence of 
neuropathy was < 2%27. 
The following factors increase the 
susceptibility to nerve damage: Poor blood 
sugar control, Length of time the patient has 
diabetes, Age, Sex, High cholesterol, 
Smoking28. 
The American Diabetes Association 
recommends that glycosylated haemoglobin 
(HbA1c) should be less than 7%9-10. Most 
previous studies, which reported HbA1c 
correlation with polyneuropathy, used 
higher HbA1c cut points and focused on 
neurologically symptomatic patients.  
We showed in our results that diabetic 
patients had poor glucose control as 
indicated by high Haemoglobin A1c as it was 
10.06 ± 1.91 in symptomatic DN patients and 
8.58 ± 1.41 in asymptomatic. Hyperinsuline-
mia and hyperglycaemia might affect 
through their co-morbidities as hyper-
tension, dyslipidemia, and central body fat 
distribution29-30.  
Hypertension was found in 57.8% of our 
diabetic patients with no statistically 
significant difference between males and 
females. The mean age of diabetic patients 
was significantly higher in hypertensive 
than non-hypertensive. There were only 
14.2% of hypertensive diabetic patients in 
whom blood pressure was controlled. Poor 
control was significantly associated with 
obesity, and a higher rate of complications, 
so our results are in agreement with what 
was reported that the blood pressure control 
correlated positively and significantly with 
the age of patients, and negatively with 
duration of diabetes and hypertension as 
observed regarding the anthropometrical 
variables, the BMI values obtained about the 
excessive weight in all groups' patients are 
similar to those found in a multi-centric 
study carried out with more than 2,500 type 
II DM patients in 12 cities of different 
Brazilian regions31-32. The high prevalence of 
overweight diabetic patients has been 
appointed by epidemiological research in 
the South and Southeast of Kingdom of 
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Saudi Arabia, estimating that between 80 
and 90% of individuals with type II DM are 
obese or overweight33. 
However, despite awareness about the 
importance of excessive body weight for 
morbidity and mortality of patients with 
type II DM, the control of this variable in 
diabetic populations has rarely been 
emphasized in most studies. In addition, the 
approach to this problem in basic health 
care has been neglected, since 
recommendations on the control of these 
variables exist in most services, but are not 
accompanied by resources that can 
adequately support individuals in an 
effective change that results in weight loss34. 
Laboratory data indicate high prevalence of 
dyslipidemia in our patients, similar to that 
found in a survey with type II DM patients, 
performed in Rio Grande do Sul 67% 
presented total cholesterol over 200mg/dL; 
65% triglycerides > 150 mg/dL and 47% low 
HDL cholesterol >50 mg/dL34. Peripheral 
neuropathy is a common clinical problem 
confronting the practicing neurologist. 
Several groups have demonstrated a 30% to 
45% prevalence of impaired glucose 
tolerance (IGT) in patients with otherwise 
idiopathic neuropathy35. In concordance 
with the results of the DCCT, UKPDS and 
Booya et al, our study shows the same risk 
factors published in different reports such as 
poor blood sugar control, the duration of 
having diabetes, the age, the high level of 
low-density lipoprotein (LDL) cholesterol 
which damaged the small blood vessels that 
nourish the nerves, and smoking where they 
enhance the atherosclerotic effect and 
reduce the blood flow to the legs and feet 
ending in damage of the peripheral  
nerves36-38. Other researchers reported that 
the diabetic neuropathy was significantly 
associated with age, duration of disease, 
negative association with arterial blood 
pressure, smoking status, low HDL 
cholesterol level, high triglyceride level, BMI 
and HbA1c 38-42. 
The diabetic individuals were, on average, 
more obese than the control group, with 
higher values for body mass index (BMI), 
Waist Hip Ratio and percentage body fat. 
The mean systolic and diastolic blood 
pressures were higher in the diabetic group 
than in the control group, as was the serum 
triglyceride43.  
Our results showed no statistical significant 
differences and there was no correlation 
between the diabetes mellitus type I and 
type II and the risk factors score which 
indicates that the risk factor effects were 
equal in both types of diabetes mellitus. 
Our study is in agreement with Tesfaye et 
al, and DCCT findings, that the mean 
glycosylated haemoglobin had a strong 
correlation with neuropathy35,44.  
Clinical spectrum of diabetic neuropathy is 
variable; it may be asymptomatic, but once 
established as neuropathy, it is irreversible 
and may finally be disabling. We 
determined the nerve conduction defects in 
asymptomatic diabetic patients. 
Our study results are in agreement with the 
results of EL-Salem et al which showed a 
correlation between elevated glycosylated 
hemoglobin and subclinical neuropathy in 
neurologically asymptomatic diabetic 
patients and the authors recommended that 
therapies for diabetic neuropathy should 
target the early stages of the disease29. 
Karsidag et al reported that there is a 
correlation between HbA1c levels and nerve 
conduction velocity in posterior tibial and 
peroneal nerves. However, upper extremity 
nerve conduction dysfunction was not 
correlated with HbA1c value45. Neither the 
duration of disease nor the age of the subject 
correlated with the nerve dysfunction, and 
that group reported that the percentages of 
abnormal electrophysiological parameters in 
different motor and sensory nerves were 
86.7% in sural nerve, 83.3% in peroneal 
motor nerve, 73.3% in posterior tibial motor 
nerve, 66.7% in median motor nerve, 63.3% 
in ulnar motor nerve, 60% in median 
sensory nerve, and 46.7% in ulnar sensory 
nerve. While distal motor latency, F 
conduction time, and minimum F latency 
were the most frequent abnormal 
parameters in the upper extremity 
electrophysiological study; conduction 
velocity, minimum and mean F latencies, F 
conduction time were the most frequent 
abnormal parameters in the lower extremity 
and in all sensory nerve conduction studies, 
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the most frequent abnormal parameter was 
the onset latency. 
Baba M, and Ozaki I, 2001 the prevalence of 
subclinical diabetic polyneuropathy in the 
United Arab of Emirates UAE, and they 
found close association between neuro-
logical deficit score and abnormalities in 
NCS46. Among various parameter of 
systemic nerve conduction studies in 
subclinical patients, prolonged F-wave 
latency seems the commonest abnormality 
suggesting morphological changes in 
subclinical diabetic nerves. 
 
Conclusion 
In conclusion, neuropathy was diagnosed in 
79% of our diabetic patients by a 
combination of clinical findings and 
electrophysiological studies (EPS). This is a 
worrying prevalence, especially as it was 
picked up in 44% of asymptomatic patients 
by (EPS). This should be emphasized in the 
care of our diabetics. Further studies needed 
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Appendix 1: Physical Assessment (To be completed by health professional). 
 
APPEARANCE OF FEET RIGHT LEFT 
Normal Yes (0), If no, check all that apply:  Yes (0), If no, check all that apply: 
Deformities Yes (0) No (1) Yes (0) No (1) 
Dry skin, callus Yes (0) No (1) Yes (0) No (1) 
Infection Yes (0) No (1) Yes (0) No (1) 
Fissure Yes (0) No (1) Yes (0) No (1) 
Ulceration Present (0) Absent (1) Present (0) Absent (1) 
Other - specify:     
Ankle Reflexes Present (0) 
Reinforce




ment (0.5) Absent (1) 









(0.5) Absent (1) 
Monofilament Normal (0) 
Reduced 




(0.5) Absent (1) 







Appendix 2: Michigan Neuropathy Screening Instrument. 
 
History (To be completed by the person with diabetes) Yes No 
1. Are you legs and/or feet numb? 1 2 
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2. Do you ever have any burning pain in your legs and/or feet? 1 2 
3. Are your feet too sensitive to touch? 1 2 
4. Do you get muscle cramps in your legs and/or feet? 1 2 
5. Do you ever have any prickling feelings in your legs or feet? 1 2 
6. Does it hurt when the bed covers touch your skin? 1 2 
7. When you get into the tub or shower, are you able to tell the hot water from the cold water? 1 2 
8. Have you ever had an open sore on your foot? 1 2 
9. Has your doctor ever told you that you have diabetic neuropathy? 1 2 
10. Do you feel weak all over most of the time? 1 2 
11. Are your symptoms worse at night? 1 2 
12. Do your legs hurt when you walk? 1 2 
13. Are you able to sense your feet when you walk? 1 2 
14. Is the skin on your feet so dry that it cracks open? 1 2 
15. Have you ever had an amputation? 1 2 
Total score:   
 
